Evidence map›Paper›PMID 25950479›Full record

ArticleCell death & disease2015

Ubiquinone-binding site mutagenesis reveals the role of mitochondrial complex II in cell death initiation.

K Kluckova, M Sticha, J Cerny, T Mracek, L Dong, Z Drahota, E Gottlieb, J Neuzil, J Rohlena

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A Novel Human SDHA-Knockout Cell Line Model for the Functional Analysis of Clinically Relevant SDHA Variants.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  6. Review
  7. Review
  8. Succinate dehydrogenase complex subunit C: Role in cellular physiology and disease.Experimental biology and medicine (Maywood, N.J.) · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Mitochondrial complex II and reactive oxygen species in disease and therapy.Redox report : communications in free radical research · 2020
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

K KluckovaInstitute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
M StichaFaculty of Sciences, Charles University, Prague, Czech Republic.
J CernyInstitute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
T MracekInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
L DongSchool of Medical Science, Griffith University, Southport, Queensland, Australia.
Z DrahotaInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
E GottliebThe Beatson Institute for Cancer Research, Glasgow, UK.
J Neuzil1] Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic [2] School of Medical Science, Griffith University, Southport, Queensland, Australia.
J RohlenaInstitute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.ORCID 0000000154276502
Czech Academy of Sciences · CZGriffith University · AUCancer Research UK Scotland Institute · GBCharles University · CZ

Funding

Cancer Research UK 18278
6 · The paper itself

Abstract

Respiratory complex II (CII, succinate dehydrogenase, SDH) inhibition can induce cell death, but the mechanistic details need clarification. To elucidate the role of reactive oxygen species (ROS) formation upon the ubiquinone-binding (Qp) site blockade, we substituted CII subunit C (SDHC) residues lining the Qp site by site-directed mutagenesis. Cell lines carrying these mutations were characterized on the bases of CII activity and exposed to Qp site inhibitors MitoVES, thenoyltrifluoroacetone (TTFA) and Atpenin A5. We found that I56F and S68A SDHC variants, which support succinate-mediated respiration and maintain low intracellular succinate, were less efficiently inhibited by MitoVES than the wild-type (WT) variant. Importantly, associated ROS generation and cell death induction was also impaired, and cell death in the WT cells was malonate and catalase sensitive. In contrast, the S68A variant was much more susceptible to TTFA inhibition than the I56F variant or the WT CII, which was again reflected by enhanced ROS formation and increased malonate- and catalase-sensitive cell death induction. The R72C variant that accumulates intracellular succinate due to compromised CII activity was resistant to MitoVES and TTFA treatment and did not increase ROS, even though TTFA efficiently generated ROS at low succinate in mitochondria isolated from R72C cells. Similarly, the high-affinity Qp site inhibitor Atpenin A5 rapidly increased intracellular succinate in WT cells but did not induce ROS or cell death, unlike MitoVES and TTFA that upregulated succinate only moderately. These results demonstrate that cell death initiation upon CII inhibition depends on ROS and that the extent of cell death correlates with the potency of inhibition at the Qp site unless intracellular succinate is high. In addition, this validates the Qp site of CII as a target for cell death induction with relevance to cancer therapy.

Indexed as

Amino Acid SequenceBinding SitesCell DeathElectron Transport Complex IIHumansMitochondriaMolecular Sequence DataMutagenesis, Site-DirectedProtein ConformationUbiquinoneElectron Transport Complex IIrespiratory complex IIUbiquinone

Identifiers

PMID25950479
PMCPMC4669690
OpenAlexW1757334295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.